Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPID | Q08752 | 7/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | PPIB | P23284 | 1/20 | 0.39 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.37 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19429945 | 0.87 | PPID (0.47) | PPIDLTA4HPPIBPRMT3RAB9A | |
| SCHEMBL19430092 | 0.86 | PPID (0.43) | PPIDLTA4HMEN1POLBKMT2A | |
| SCHEMBL19423585 | 0.85 | CYP4F2 (0.43) | PPIDLTA4HRAB9APOLB | |
| SCHEMBL19429983 | 0.84 | PPID (0.45) | PPIDPPIBMEN1POLBKMT2A | |
| SCHEMBL19429924 | 0.84 | PPID (0.45) | PPIDPPIBMEN1POLBKMT2A | |
| SCHEMBL19429764 | 0.82 | PPID (0.44) | PPIDPPIBMEN1POLBKMT2A | |
| SCHEMBL19423584 | 0.81 | PPID (0.55) | PPIDLTA4HPPIBPRMT3RAB9A | |
| SCHEMBL19423583 | 0.81 | PPID (0.47) | PPIDPPIBPRMT3AVPR2BAZ1A | |
| SCHEMBL19423764 | 0.79 | PPID (0.70) | PPIDPPIB | |
| SCHEMBL19423566 | 0.79 | PPID (0.70) | PPIDPPIB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283425-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-10-05 | — | — | US | disclosed |
| WO-2017173048-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283425-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | PPIG, PPIH, FKBP2 | PPID 17/4885LTA4H 1536/4885PPIB 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.